Reflections on the Future of Pharmaceutical Public-Private Partnerships: From Input to Impact

Remco L A de Vrueh; Daan J A Crommelin

doi:10.1007/s11095-017-2192-5

Reflections on the Future of Pharmaceutical Public-Private Partnerships: From Input to Impact

Remco L A de Vrueh, Daan J A Crommelin

Pharmaceutics

Lygature, Utrecht, The Netherlands.
Department of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences, UIPS, Utrecht University, Utrecht, The Netherlands. [email protected].

Research output: Contribution to journal › Review article › peer-review

Abstract

Public Private Partnerships (PPPs) are multiple stakeholder partnerships designed to improve research efficacy. We focus on PPPs in the biomedical/pharmaceutical field, which emerged as a logical result of the open innovation model. Originally, a typical PPP was based on an academic and an industrial pillar, with governmental or other third party funding as an incentive. Over time, other players joined in, often health foundations, patient organizations, and regulatory scientists. This review discusses reasons for initiating a PPP, focusing on precompetitive research. It looks at typical expectations and challenges when starting such an endeavor, the characteristics of PPPs, and approaches to assessing the success of the concept. Finally, four case studies are presented, of PPPs differing in size, geographical spread, and research focus.

Original language	English
Pages (from-to)	1985-1999
Number of pages	15
Journal	Pharmaceutical Research
Volume	34
Issue number	10
DOIs	https://doi.org/10.1007/s11095-017-2192-5
Publication status	Published - 2017

Keywords

key drivers
performance evaluation
public-private-partnerships
R&D business models

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1007/s11095-017-2192-5

vruehFinal published version, 774 KB

Cite this

@article{f8f47cb65e724c74a7656dc45ab5dc8b,

title = "Reflections on the Future of Pharmaceutical Public-Private Partnerships: From Input to Impact",

abstract = "Public Private Partnerships (PPPs) are multiple stakeholder partnerships designed to improve research efficacy. We focus on PPPs in the biomedical/pharmaceutical field, which emerged as a logical result of the open innovation model. Originally, a typical PPP was based on an academic and an industrial pillar, with governmental or other third party funding as an incentive. Over time, other players joined in, often health foundations, patient organizations, and regulatory scientists. This review discusses reasons for initiating a PPP, focusing on precompetitive research. It looks at typical expectations and challenges when starting such an endeavor, the characteristics of PPPs, and approaches to assessing the success of the concept. Finally, four case studies are presented, of PPPs differing in size, geographical spread, and research focus.",

keywords = "key drivers, performance evaluation, public-private-partnerships, R&D business models",

author = "{de Vrueh}, {Remco L A} and Crommelin, {Daan J A}",

year = "2017",

doi = "10.1007/s11095-017-2192-5",

language = "English",

volume = "34",

pages = "1985--1999",

journal = "Pharmaceutical Research",

issn = "0724-8741",

publisher = "Springer",

number = "10",

}

TY - JOUR

T1 - Reflections on the Future of Pharmaceutical Public-Private Partnerships

T2 - From Input to Impact

AU - de Vrueh, Remco L A

AU - Crommelin, Daan J A

PY - 2017

Y1 - 2017

N2 - Public Private Partnerships (PPPs) are multiple stakeholder partnerships designed to improve research efficacy. We focus on PPPs in the biomedical/pharmaceutical field, which emerged as a logical result of the open innovation model. Originally, a typical PPP was based on an academic and an industrial pillar, with governmental or other third party funding as an incentive. Over time, other players joined in, often health foundations, patient organizations, and regulatory scientists. This review discusses reasons for initiating a PPP, focusing on precompetitive research. It looks at typical expectations and challenges when starting such an endeavor, the characteristics of PPPs, and approaches to assessing the success of the concept. Finally, four case studies are presented, of PPPs differing in size, geographical spread, and research focus.

AB - Public Private Partnerships (PPPs) are multiple stakeholder partnerships designed to improve research efficacy. We focus on PPPs in the biomedical/pharmaceutical field, which emerged as a logical result of the open innovation model. Originally, a typical PPP was based on an academic and an industrial pillar, with governmental or other third party funding as an incentive. Over time, other players joined in, often health foundations, patient organizations, and regulatory scientists. This review discusses reasons for initiating a PPP, focusing on precompetitive research. It looks at typical expectations and challenges when starting such an endeavor, the characteristics of PPPs, and approaches to assessing the success of the concept. Finally, four case studies are presented, of PPPs differing in size, geographical spread, and research focus.

KW - key drivers

KW - performance evaluation

KW - public-private-partnerships

KW - R&D business models

U2 - 10.1007/s11095-017-2192-5

DO - 10.1007/s11095-017-2192-5

M3 - Review article

C2 - 28589444

SN - 0724-8741

VL - 34

SP - 1985

EP - 1999

JO - Pharmaceutical Research

JF - Pharmaceutical Research

IS - 10

ER -

Reflections on the Future of Pharmaceutical Public-Private Partnerships: From Input to Impact

Abstract

Keywords

UN SDGs

Access to Document

Fingerprint

Cite this